| 摘要: |
| ［摘要］ 目的 分析FIRST简易版虚弱评估量表评分在新诊断多发性骨髓瘤（NDMM）患者中的应用价值。方法 回顾性分析2014年7月1日至2021年12月31日山西医科大学第三医院收治的131例NDMM患者的临床资料。根据FIRST简易版虚弱评估量表评分将其分为虚弱组（50例）和非虚弱组（81例）。比较两组患者疗效、累积早期≥3级感染发生率及生存预后情况。并对接受硼替佐米为基础诱导治疗方案的患者进行亚组分析。结果 两组疗效为≥非常好的部分缓解（VGPR）的人数比例差异无统计学意义（45.68% vs 36.00%，P>0.05）。虚弱组和非虚弱组分别有26例（52.00%）和27例（33.33%）发生早期≥3级感染，虚弱组早期≥3级感染相关预后更差（log-rank检验： χ2=4.472，P=0.020）。虚弱组中位总生存（OS）时间和中位无进展生存（PFS）时间均短于非虚弱组（36个月 vs 81个月；16个月 vs 34个月），非虚弱组生存预后情况显著优于虚弱组（P<0.05）。在接受硼替佐米为基础诱导方案治疗的100例患者中，虚弱组中位OS时间和中位PFS时间均短于非虚弱组（34个月 vs 84个月；15个月 vs 33个月），非虚弱组生存预后情况显著优于虚弱组（P<0.05）。结论 FIRST简易版虚弱评估量表评分对NDMM患者有较好的应用价值。 |
| 关键词: 多发性骨髓瘤 FIRST简易版虚弱评估量表 虚弱 感染 预后 |
| DOI：10.3969/j.issn.1674-3806.2024.02.11 |
| 分类号:R 733.3 |
| 基金项目: |
|
| Analysis on the application value of FIRST simplified frailty scale score in patients with newly diagnosed multiple myeloma |
|
YAO Qiong1,2, WANG Xinwei1, YANG Hui2, LI Linyu2, ZHAO Jie2, HE Shaolong2, TIAN Weiwei2
|
|
1.Shanxi Medical University, Taiyuan 030000, China; 2.Department of Hematology, the Third Hospital of Shanxi Medical University(Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital), Taiyuan 030032, China
|
| Abstract: |
| ［Abstract］ Objective To analyze the application value of FIRST simplified frailty scale score in patients with newly diagnosed multiple myeloma(NDMM). Methods The clinical data of 131 patients with NDMM who were admitted to the Third Hospital of Shanxi Medical University from July 1, 2014 to December 31, 2021 were retrospectively analyzed. The patients were divided into frailty group(50 cases) and non-frailty group(81 cases) according to different FIRST simplified frailty scale scores. The therapeutic effect, cumulative incidence of early grade ≥3 infection and survival prognosis were compared between the patients in the two groups. Subgroup analysis was performed for the patients receiving bortezomib-based induction therapy scheme. Results There was no significant difference in the proportion of the patients with therapeutic effect being more than or equal to very good partial response(VGPR) between the two groups(45.68% vs 36.00%, P>0.05). There were 26 cases(52.00%) and 27 cases(33.33%) of early grade ≥3 infection in the frailty group and the non-frailty group, respectively. The prognosis of the patients related to early grade ≥3 infection in the frailty group was worse than that in the non-frailty group(log-rank test: χ2=4.472, P=0.020). The median overall survival(OS) time and median progression-free survival(PFS) time in the frailty group was shorter than that in the non-frailty group(36 months vs 81 months; 16 months vs 34 months), and the survival prognosis of the non-frailty group was significantly better than that of the frailty group(P<0.05). Among the 100 patients receiving the therapy of bortezomib-based induction scheme, both the median OS time and the median PFS time in the frailty group was shorter than that in the non-frailty group(34 months vs 84 months; 15 months vs 33 months), and the survival prognosis of the non-frailty group was significantly better than that of the frailty group(P<0.05). Conclusion FIRST simplified frailty scale score has relatively good application value for patients with NDMM. |
| Key words: Multiple myeloma FIRST simplified frailty scale Frailty Infection Prognosis |
